



Deeply clever.



**Nebulize high value
therapeutic drugs**

About HCmed



Leading Mesh Platform specializes in drug-device combination development with proprietary Vibrating Mesh Technology



Chairman/CEO
Jason Cheng

✓ Electrical
System



Board Director/COO
Leon Tsai

✓ System
Integration



Board Director
**Mahendra G.
Shah, Ph.D.**

✓ Formulation
Combination



Board Director
Simon Hsieh

✓ Production
Automation



Co-Founder
**Shaogi Huang,
MD**

✓ Pediatrician &
Cardiologist



Proprietary Facility



Dedicated Employees



HQ/R&D Center



Inhalation Research Lab




GMP Production Facility

Our Business Model



VMT mkt fastest growth is driven by modern technology, surge of clinical trials & high value drugs

16% CAGR of Clinical Trial²



18% Growth in High Value Drugs

Biologics


- 2017 mAb market exceeded US\$98 billion with 9.7% targeting pulmonary related diseases.^{3, 4}

Suspension

- The annual sales of Pulmicort® in emerging market reach to \$995m, 77% of global market.⁵

Choosing the professional solution with reasonable cost will increase the patient's medication adherence

Efficacy of nebulizers delivering suspension⁶



■ Aeroneb Pro



■ Omron NE-U22



■ Pari- Air Jet



■ Ultrasonic



NI = Not investigated

Cost-effectiveness analyses

To Payers

- Considerable cost-savings

To Patients

- From expensive hospital-based rescue to community-based prevention.⁷

The challenges of mesh nebulizer⁸

- Limited output rate
- Drug aggregations

The Cost

- The mesh nebulizers delivering difficult drug formulations cost higher than \$700.

Technology Highlights

Efficient Delivery with
Reasonable Price

High Value Therapeutic
Drug combination

ONE Clear™

Micro Synchronized
Technology

Highly Integrated for
Cost Efficiency




Suspension

Antibiotics

High Viscosity &
Biologics

Efficient Delivery & Tailor Design

✓ Deepro vs. Philips (Innospire Go) Budesonide Delivery





✓ Deepro - the most efficient mesh nebulizer deliver Budesonide

Budesonide (1mg/2ml) Device 2 (Standard Deepro)	Deliver dose(mg)	FPD(mg)	FPF(%)	MMAD (um)
1 st NGI same day	0.486	0.223	45.81	4.98
2 nd NGI same day (w/o wash)	0.468	0.216	46.23	4.91
3 rd NGI same day (w/o wash)	0.465	0.216	46.05	4.92
6 th NGI after 5 days (w/o wash)	0.544	0.258	47.4	4.75
1 st NGI after water wash	0.471	0.218	46.28	4.91

ONE Clear™

Turn-on
in the water

> 99.5% clog
removed



High Value Therapeutic Drug Combination

Expanding Partnerships



Pharma	Location	Drugs	Type	Target
A	Italy	Suspension	505(b)2	Orphan, Combination
B	Sweden	Suspension	505(b)2	Asthma, Combination
C	India	Suspension	505(b)2	COPD, Combination
D	China	Suspension	Class II new drug	Asthma, Combination
E	Switzerland	Biologics & High viscosity	505(b)2	Lung infection

Certifications



✓ Approved by health authorities and ready for combination development.

Global Partners - Licensing, Development, and Supply

Partner	Business Model	Drug Type	Status
A Company	Licensing & Supply in Brazil	Approved Drug	Launch in May, 2019
	Drug-Device Combination	Class II New drug (Antibiotics)	Clinical Stage
	Licensing & Supply	Approved Drug	Est. 2019Q4 launch

GMP certificated manufacturing facility



inA!Resp Nebulizador PORTÁTIL



Silencioso
Compacto
Prático e Lave

PARTÍCULA FINA
Linha de partícula
PROFUNDAMENTE nas pulmões

deepro
FARMACIA DE PRODUTOS

IMAGEM NÃO REPRESENTA UM TUBO REAL



THANK YOU

For more detail, please contact
Jason@HCmed-inno.com

Reference

1. FMI, Future Market Insight 2015 report
2. Ther. Deliv. (2018) 9(2), 121–136
3. Trends in Biotechnology, January 2019, Vol. 37, No. 1
4. MAbs. 2014;6(5):1347-55. doi: 10.4161/mabs.29938. Epub 2014 Oct 30.
5. AstraZeneca annual report 2018
6. International Journal of Pharmaceutics 461 (2014) 234– 241
7. Pharmacoeconomics, 35 (6). pp. 647-659. ISSN 1170-7690
8. Eurasian J Pulmonol 2014; 16: 1-7